About UCB
UCB is a publicly listed company based in Brussels (Belgium) founded in 1928. Therapies for immunological and neurological disorders are developed. UCB has completed 9 acquisitions, including Be4, Element Genomics and Engage Therapeutics. Its website ucb.com draws about 147 thousand monthly visits. Its Indian entity Ucb India Private Limited reported revenue of ₹32.54 Cr. Its focus areas include Traditional Pharmaceuticals.
Company details
UCB was founded in 1928 and is headquartered in Brussels, Belgium. Focus is placed on the pharmaceutical sector, where therapies for immunological and neurological disorders are developed. Operations encompass the creation and distribution of medications such as Briviact, Vimpat, and Keppra for epilepsy treatment; Neupro for Parkinsons disease; and Cimzia for rheumatoid arthritis. Additional products are maintained in the portfolio to address related conditions globally.
- Indian entity revenue₹32.54 Cr
FY 2022 · -7% YoY
- Indian entity net profit₹6.02 Cr
FY 2022 · 18% margin
- Indian entity EBITDA₹5.25 Cr
FY 2022 · 16% margin
- Latest Funding Round$301.94K (USD), Grant
Jan 2020
- InvestorsEuropean Union
& 1 more
- Investments & AcquisitionsBe4
& 8 more
Associated legal entities of UCB
UCB is associated with 2 registered companies on The Company Check; the primary company is Ucb India Private Limited. Each company page carries the filings, financials, charges and directors of that entity.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2022) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Ucb India Private Limited CIN U62090MH1959PTC011545 | Active | 18 Dec 1959 | Bhiwandi, Maharashtra | ₹32.5 Cr | 14 | 3 | View details |
| Ucb India Private Limited CIN U24239MH1959PTC011545 | Active | 18 Dec 1959 | Thane, Maharashtra, India | View details |
Apps and channels of UCB
its YouTube channel UCB has 2.63K subscribers and 30 videos.
Videos from UCB
The most watched videos on UCB's YouTube channel, UCB (2.63K subscribers). Click a video to play it here.
More on UCB.
Funding Insights of UCB
- Total Rounds 6
- Last Round Grant — $301,942
- First Round $100M
(Dec 2009)
- Investors Count 2
All 6 funding rounds of UCB with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2020 | $301,942 | Grant | – | – | |
| Feb 2016 | $272,998 | Grant | – | – | |
| Jan 2016 | $272,108 | Grant | – | – | |
| May 2015 | $787,628 | Post-IPO | – | – | – |
| Jan 2015 | $633,259 | Grant | – | – | |
| Dec 2009 | $100M | Post-IPO | – | – |
2 investors in total: 2 institutional.
Investors in UCB
UCB has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include European Union and Paul Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
Functions as a diversified investor in secondary markets. | 1991 | paulcap.com | San Francisco, United States |
Investor details for UCB
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Ucb India Private Limited (UCB)
Ucb India Private Limited is the primary company behind UCB. The board of Ucb India Private Limited currently have 3 directors; the longest-serving is Patrick Francois R Nonnon, appointed in 2018. 12 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Patrick Francois R Nonnon DIN 08296526 | Director | 19 Dec 2018 | 7 yrs 10 mo | Ucb India Private Limited |
| Vaishali Arvind Paradkar DIN 08540735 | Director | 28 Aug 2019 | 7 yrs 2 mo | Ucb India Private Limited |
| Smita Godfrey Dsilva DIN 03604334 | Director | 17 Apr 2025 | 1 yr 6 mo | Ucb India Private Limited |
People of UCB
820 people are tracked at UCB (331 in leadership, 489 in team).
| Name | Role | Group |
|---|---|---|
Milena Iwańska | Senior Strategic Sourcing Partner At Randstad Sourceright On Behalf Of UCB | Leadership |
Catrinel Galateanu | Vp, Global Patient Community Head Immunology | Leadership |
Jean-Luc Fleurial | Executive Vice President & Chief Human Resources Officer | Leadership |
Sandrine Dufour | Executive Vice President & Chief Financial Officer | Leadership |
Sathish Kumar | Head Of Digital Technology - Patient Supply, Corporate Functions & ERP | Leadership |
Frédéric Septon | Learning & Development Partner | Leadership |
Agathe Maury - le Breton | Global Access Insights & Strategic Pricing HEAD | Leadership |
Nassim Haddad | Head Of IT Artificial Intelligence (senior Director) | Leadership |
Lisa Walsh | Rheumatology Franchise Head | Leadership |
Baran Ufuktepe | Global Rheumatology Medical Community Head | Leadership |
Taco van Tiel | Head UCB USA | Leadership |
Serkan Oray | Vice President, Head Of Devices, Artwork & Packaging | Leadership |
Federico Chinni | General Manager | Leadership |
Guendalina van Gyseghem | Director, Medical Devices Program Lead At UCB | Leadership |
Magali Courtin | Head Of External Research Opportunities | Leadership |
Tonya Adams | US Head-diversity, Equity And Inclusion | Leadership |
Paul Kusters | Head Strategic Operations | Leadership |
Quentin Hamouch | Head Of Patient Supply Digital Transformation | Leadership |
Baldur Magnusson | Executive Director - Head Late Development Statistics | Leadership |
Edwin Erckens | Chief Digital Technology Officer | Leadership |
800 more people are available in the full profile.
Complete people profiles for UCB
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of UCB
Figures of Ucb India Private Limited, the primary company behind UCB, for FY 2022. Revenue was ₹32.54 Cr (-7% year on year). Net profit was ₹6.02 Cr (18% margin). EBITDA was ₹5.25 Cr (16% margin). Revenue has grown at a compounded annual rate of -11% over three years.
- ₹32.54 CrRevenue · FY 2022 · -7% YoY
- ₹6.02 CrNet profit · 18% margin
- ₹5.25 CrEBITDA · 16% margin
- ₹35.3 LakhPaid-up capital
- 14Employees (provident fund records)
- -11%Revenue CAGR, 3 years
Balance sheet, profit and loss, cash flow and ratios of Ucb India Private Limited are on its company page.
Detailed financial statements for UCB
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by UCB
UCB has strategically engaged in corporate development activities, having acquired 9 companies. Notable acquisitions include Be4, Element Genomics and Engage Therapeutics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Cell-based therapies are developed for intractable neurological diseases. | neuronatherapeutics.com | San Francisco, United States | 2008 | Apr 2026 | $650M | |
Drug delivery systems for CNS disorders and pain are developed. | zogenix.com | Emeryville, United States | 2006 | Jan 2022 | •••• | |
Developer of gene therapy to treat neurodegenerative diseases | handltherapeutics.com | Leuven, Belgium | 2019 | Nov 2020 | •••• | |
Inhaled drug-device combo as rescue treatment for uncontrolled epileptic seizures | engagetherapeutics.com | Summit, United States | 2017 | Jun 2020 | $125M | |
Complement system inhibitors using peptides are developed for rare diseases. | rapharma.com | Cambridge, United States | 2008 | Oct 2019 | $2.5B | |
An epigenomic editing platform is developed to identify drug targets. | elementgenomics.com | Durham, United States | 2015 | Apr 2018 | $30M | |
Drug discovery solutions are offered by Beryllium through specialized services. | be4.com | Bedford, United Kingdom | 2009 | Jun 2017 | •••• | |
Develops innovative small molecule therapeutics for effective pain management. | lectustherapeutics.com | Cambridge, United Kingdom | 2002 | Nov 2011 | •••• | |
Drugs for cardiovascular system, gastrointestinal tract ,asthma, neurology and urology | schwarzpharma.com | Monheim, Germany | 1946 | Sep 2006 | $5.6B |
Complete acquisition details for UCB
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of UCB
13 dated milestones of UCB across 98 years, from founding to its latest funding, stage changes and deals.
- Founded UCB is founded.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Schwarz Pharma.
- Funding First funding round of $100.0M.
- Acquisition Acquires Lectus Therapeutics.
- Acquisition Acquires Be4.
- Acquisition Acquires Element Genomics.
- Acquisition Acquires Ra Pharmaceuticals.
- Funding Latest funding round, Grant, of $302K.
- Acquisition Acquires Engage Therapeutics.
- Acquisition Acquires Handl Therapeutics.
- Acquisition Acquires Zogenix.
- Acquisition Acquires Neurona Therapeutics.
Web traffic of UCB
The website of UCB (ucb.com) receives about 146.5K visits a month and ranks #308,606 among all websites worldwide, #10,769 in Health.
- Monthly visits146.5K
▲ 15.8% vs previous month
- Unique visitors53.6K
per month
- Global rank#308,606
among all websites
- Category rank#10,769
Health · Health
- Bounce rate41%
- Pages per visit2.2
- Average visit1 min 02 sec
- DevicesDesktop 43% · Mobile 57%
Websites whose visitors overlap most with UCB. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| abbott.com | 100% | 917.2K | #65,577 | View details | |
| gsk.com | 99% | 1.3M | #56,834 | View details | |
| bms.com | 87% | 809.8K | #67,210 | View details | |
| boehringer-ingelheim.com | 85% | 1.6M | #39,825 | View details | |
| lilly.com | 84% | 4.9M | #13,252 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for UCB
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Ucb
Complete news archive for UCB
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about UCB
UCB was founded in 1928 and raised its 1st funding round 81 years after it was founded.
UCB is headquartered in Brussels, Belgium. It is registered at Brussels, Brussels-capital Region, Belgium.
The primary company behind UCB, Ucb India Private Limited, reported revenue of ₹32.54 Cr for FY 2022, down 7% year on year.
UCB was founded in 1928 and is headquartered in Brussels, Belgium. Focus is placed on the pharmaceutical sector, where therapies for immunological and neurological disorders are developed. Operations encompass the creation and distribution of medications such as Briviact, Vimpat, and Keppra for epilepsy treatment; Neupro for Parkinsons disease; and Cimzia for rheumatoid arthritis. Additional products are maintained in the portfolio to address related conditions globally.
UCB has made 9 acquisitions, including Be4, Element Genomics, and Engage Therapeutics.
UCB has 2 investors. Key investors include European Union, and Paul Capital.
UCB operates through Ucb India Private Limited.
The legal entities of UCB currently have 3 directors, including Smita Godfrey Dsilva, Vaishali Arvind Paradkar, Patrick Francois R Nonnon.
The website of UCB receives about 147 thousand visits a month and ranks #308,606 among all websites worldwide.